Transcatheter @entity1416 for endoscopically unmanageable non-variceal upper XXXX .

@entity1 @entity548 @entity5 @entity1416 @entity1003 @entity177 @entity99 @entity360
UNASSIGNED: Abstract Objective. Transcatheter @entity1416 (TAE) is a therapeutic option for endoscopically unmanageable upper @entity360 . We aimed to assess the efficacy and clinical outcomes of TAE for acute @entity360 and to identify predictors of recurrent @entity548 within 30 days. Materials and methods. Visceral angiography was performed in 66 @entity1 (42 @entity1 , 24 @entity1 ; mean age, 60.3    12.7 years) who experienced acute @entity360 that failed to be controlled by endoscopy during a 7-year period. Clinical information was reviewed retrospectively. Outcomes included technical success rates, complications, and 30-day rebleeding and mortality rates. Results. TAE was feasible in 59 @entity1 . The technical success rate was 98%. Rebleeding within 30 days was observed in 47% after an initial TAE and was managed with re-embolization in 8, by endoscopic intervention in 5, by surgery in 2, and by conservative care in 12 @entity1 . The 30-day overall mortality rate was 42.4%. In the case of initial @entity177 (n = 34), 31 @entity1 underwent angiographic embolization, which was successful in 30 @entity1 (96.8%). Rebleeding occurred in 15 @entity1 (50%), mainly because of @entity5 . Two factors were independent predictors of rebleeding within 30 days by multivariate analysis: @entity1003 (odds ratio [OR] = 4.37; 95% confidence interval [CI]: 1.25-15.29; p = 0.021) and embolization in >= 2 territories (OR = 4.93; 95% CI: 1.43-17.04; p = 0.012). Catheterization-related complications included @entity99 . Conclusion. TAE controlled acute @entity360 effectively. TAE may be considered when endoscopic therapy is unavailable or unsuccessful. Correction of @entity1003 before TAE is recommended.
